Targets › IL5RA
4 programs from 4 companies in 18 trials: 9 Phase 3, 5 Phase 2, 3 Phase 4, 1 Phase 1; Respiratory, Immunology, Hematology; next expected readout Nov 2026.
Cell surface receptor that plays an important role in the survival, differentiation, and chemotaxis of eosinophils. Acts by forming a heterodimeric receptor with CSF2RB subunit and subsequently binding to interleukin-5. (UniProt, Q01344)
Open in Phaseline: the race on IL5RA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Benralizumab Interleukin-5 receptor subunit alpha inhibitor | IL5RA | Phase 4 | Asthma; Eosinophilic Asthma; Eosinophilic Granulomatous Vasculitis; Hypereosinophilic Syndrome … | Nov 2026 |
| Sanofi | Lunsekimig (SAR443765) IL-5 receptor alpha antagonist | IL5RA | Phase 3 | Chronic Obstructive Pulmonary Disease; Asthma; Chronic Rhinosinusitis With Nasal Polyps | Jun 2027 |
| Guangdong Hengrui Pharmaceutical | SHR-1703 Injection IL-5 receptor alpha antagonist | IL5RA | Phase 3 | Asthma With Eosinophilic Phenotype; Eosinophilic Asthma Patients; Eosinophilic Granulomatosis With Polyangiitis | Sep 2027 |
| Zhejiang University | IL-5 CAR-T cells CAR-T cells targeting IL-5 receptor alpha (CD125) | IL5RA | Phase 1 | Hematologic Diseases | Nov 2028 |
Asthma (5) Chronic Obstructive Pulmonary Disease (2) Eosinophilic Asthma (1) Eosinophilic Granulomatous Vasculitis (1) Hypereosinophilic Syndrome (1) Eosinophilic Granulomatosis With Polyangiitis (EGPA) (1) Asthma; Eosinophilic (1) Moderate to Severe Asthma (1) Chronic Rhinosinusitis With Nasal Polyps (1) Asthma With Eosinophilic Phenotype (1) Eosinophilic Asthma Patients (1) Eosinophilic Granulomatosis With Polyangiitis (1)
antibody (1), mixed (1), small molecule (1), other (1)
AstraZeneca (1) Sanofi (1) Guangdong Hengrui Pharmaceutical (1) Zhejiang University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.